HC Wainwright Analysts Give Foamix Pharmaceuticals (FOMX) a $12.00 Price Target

HC Wainwright set a $12.00 price objective on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. ValuEngine downgraded Foamix Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 4th. Cantor Fitzgerald assumed coverage on Foamix Pharmaceuticals in a research report on Thursday, October 11th. They issued an overweight rating on the stock. BidaskClub downgraded Foamix Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, October 27th. Zacks Investment Research cut Foamix Pharmaceuticals from a strong-buy rating to a hold rating in a report on Monday, October 8th. Finally, Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $13.94.

NASDAQ:FOMX opened at $4.09 on Tuesday. Foamix Pharmaceuticals has a 52-week low of $3.60 and a 52-week high of $7.60.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The company had revenue of $0.87 million during the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,049.92% and a negative return on equity of 118.29%. As a group, sell-side analysts predict that Foamix Pharmaceuticals will post -1.67 EPS for the current year.

In other Foamix Pharmaceuticals news, Director Aharon Schwartz purchased 12,200 shares of Foamix Pharmaceuticals stock in a transaction that occurred on Wednesday, November 28th. The stock was acquired at an average price of $3.88 per share, for a total transaction of $47,336.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at approximately $194,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 11,967 shares of company stock valued at $49,967 in the last quarter. 3.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. grew its holdings in Foamix Pharmaceuticals by 29.4% during the third quarter. Marshall Wace North America L.P. now owns 537,828 shares of the specialty pharmaceutical company’s stock worth $3,082,000 after purchasing an additional 122,328 shares during the period. Nexthera Capital LP bought a new position in Foamix Pharmaceuticals during the third quarter worth about $4,282,000. Point72 Asset Management L.P. bought a new position in Foamix Pharmaceuticals during the third quarter worth about $6,616,000. Sio Capital Management LLC bought a new position in Foamix Pharmaceuticals during the third quarter worth about $4,412,000. Finally, Hound Partners LLC bought a new position in Foamix Pharmaceuticals during the third quarter worth about $1,117,000. Institutional investors and hedge funds own 62.84% of the company’s stock.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

See Also: Stock Split

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit